A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

J. Harrison, Simon; C. Minnema, Monique; C. Lee, Hans; Spencer, Andrew; Kapoor, Prashant; Madduri, Deepu; T. Larsen, Jeremy; Ailawadhi, Sikander; L. Kaufman, Jonathan; S. Raab, Marc; Hari, Parameswaran; Iida, Shinsuke; Vij, Ravi; E. Davies, Faith; Lesley, Robin; Upreti, Vijay; Yang, Zhao; Sharma, Anjali; C. Minella, Alex; Lentzsch, Suzanne

doi:10.1182/blood-2020-134063

Public

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Shared by NobleBlocks on Nov 4, 2020 • 12:00 AM UTC

Authors:

Simon J. Harrison

Monique C. Minnema

Hans C. Lee

Abstract

Aims: To evaluate AMG 701, a BiTE® molecule binding BCMA on MM cells and CD3 on T cells, in RR MM (Amgen, NCT03287908); primary objective was to evaluate safety and tolerability and estimate a biologically active dose; secondary objectives were to characterize pharmacokinetics (PK), anti-myeloma act...

Subject

Medicine

Refractory (planetary science)

Antigen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!